Press release
Amyloidosis Market Massive Growth opportunity Ahead
Amyloidosis Market
Amyloidosis is a rare, progressive disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, leading to organ dysfunction and, in severe cases, life-threatening complications. The condition can affect the kidneys, heart, liver, and nervous system, making early detection and effective treatment essential. Historically underdiagnosed, amyloidosis is now gaining visibility due to advances in diagnostic tools, imaging technologies, and therapeutic innovations.
In 2024, the global Amyloidosis Market is valued at USD 6.8 billion and is projected to reach USD 13.2 billion by 2034, growing at a CAGR of 6.9% (2025-2034). Rising awareness among healthcare professionals, expansion of novel treatment options, and increased patient access to therapies are expected to drive market growth over the next decade.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71072
Market Overview
• Market Size 2024: USD 6.8 billion
• Forecast 2034: USD 13.2 billion
• CAGR (2025-2034): 6.9%
• Key Drivers: Advancements in diagnostic imaging and biopsy techniques, availability of disease-modifying therapies, rising incidence of multiple myeloma-related amyloidosis, and expanding rare disease research funding.
• Key Challenges: High treatment costs, limited awareness in developing regions, delayed diagnosis due to non-specific symptoms, and challenges in patient management.
• Leading Players: Johnson & Johnson (Janssen), Pfizer, Takeda, Bristol-Myers Squibb, Amgen, Novartis, AbbVie, Alexion Pharmaceuticals, Ionis Pharmaceuticals, GlaxoSmithKline.
The market is gradually transitioning from conventional symptomatic management to targeted disease-modifying therapies, offering new opportunities for patients and healthcare providers.
Segmentation Analysis
By Product
• Chemotherapy drugs
• Proteasome inhibitors
• Immunotherapy drugs
• Monoclonal antibodies
• Supportive care drugs
• Others
By Therapy
• Targeted therapy
• Chemotherapy
• Stem cell transplantation
• Immunotherapy
• Combination therapy
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Specialty clinics
• Online pharmacies
By End-Use
• Hospitals
• Cancer and rare disease centers
• Research institutes
• Homecare
By Application
• AL amyloidosis (primary amyloidosis)
• AA amyloidosis (secondary amyloidosis)
• Hereditary amyloidosis
• Wild-type transthyretin amyloidosis (ATTRwt)
• Dialysis-related amyloidosis
Summary of Segmentation
The AL amyloidosis segment dominates the market due to its high prevalence among patients with multiple myeloma. Targeted therapies and monoclonal antibodies are gaining rapid adoption, while hospital pharmacies remain the leading distribution channel due to the complexity of treatment regimens.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71072/amyloidosis-market
Regional Analysis
• North America: Leads the market, driven by advanced healthcare infrastructure, strong research activity, high awareness, and availability of novel therapeutics.
• Europe: Strong market presence due to widespread adoption of stem cell therapies, clinical trial participation, and supportive regulatory frameworks.
• Asia-Pacific: Fastest-growing region, with increasing healthcare expenditure, rising diagnosis rates, and expanding pharmaceutical investments in rare disease treatment.
• Middle East & Africa: Moderate growth due to underdiagnosis and limited treatment options, though improving government initiatives are expanding access.
• Latin America: Steady growth led by Brazil and Mexico, supported by increasing availability of diagnostic and treatment facilities.
Regional Trends Summary
North America and Europe dominate due to advanced infrastructure and established rare disease programs, while Asia-Pacific is projected to record the highest CAGR of over 8% between 2025 and 2034, owing to rising investments and growing patient awareness.
Market Dynamics
Key Growth Drivers
• Advancements in diagnostic imaging and laboratory techniques.
• Rising availability of targeted therapies and monoclonal antibodies.
• Growing research funding and clinical trials for rare diseases.
• Increasing prevalence of AL amyloidosis linked to multiple myeloma.
Key Challenges
• High costs associated with therapies and prolonged treatment cycles.
• Delayed diagnosis due to overlapping symptoms with other conditions.
• Limited disease awareness among physicians in developing economies.
Latest Trends
• Growing focus on RNA-based therapies and gene-silencing approaches.
• Expansion of orphan drug designations by regulatory authorities.
• Increasing adoption of stem cell transplantation for eligible patients.
• Rising pharmaceutical investment in next-generation monoclonal antibodies.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71072
Competitive Landscape
Major Players
• Johnson & Johnson (Janssen)
• Pfizer
• Takeda
• Bristol-Myers Squibb
• Amgen
• Novartis
• AbbVie
• Alexion Pharmaceuticals
• Ionis Pharmaceuticals
• GlaxoSmithKline
Competitive Insights
The Amyloidosis Market is moderately consolidated, with leading pharmaceutical companies investing in targeted therapy development and clinical trials. Strategic collaborations, regulatory approvals, and orphan drug designations are central to their growth strategies. Start-ups and biotech firms are also contributing with innovative research in RNA therapies and next-generation biologics.
Conclusion
The global Amyloidosis Market is transitioning into a new growth phase, underpinned by improved diagnostic capabilities and a stronger pipeline of therapies. From USD 6.8 billion in 2024 to USD 13.2 billion by 2034, the market is expected to grow at a CAGR of 6.9%, offering promising opportunities for healthcare providers, researchers, and industry stakeholders.
• Opportunities: Asia-Pacific expansion, development of gene-based and RNA therapies, and increasing adoption of monoclonal antibodies.
• Challenges: High cost of therapies, limited awareness in emerging economies, and delayed patient diagnosis.
• Key Takeaway: Companies focusing on innovation, affordability, and patient-centric approaches will be best positioned to capitalize on the growing amyloidosis treatment market over the next decade.
This report is also available in the following languages : Japanese (アミロイドーシス市場), Korean (아밀로이드증 시장), Chinese (淀粉样变性市场), French (Marché de l'amylose), German (Amyloidose-Markt), and Italian (Mercato dell'amiloidosi), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71072
Our More Reports:
Bacterial Vaginosis Market
https://exactitudeconsultancy.com/reports/70725/bacterial-vaginosis-market
Menopause Market
https://exactitudeconsultancy.com/reports/70727/menopause-market
Anovulation Market
https://exactitudeconsultancy.com/reports/70729/anovulation-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyloidosis Market Massive Growth opportunity Ahead here
News-ID: 4157726 • Views: …
More Releases from Exactitude Consultancy
Buerger's Disease Market Emerging Trends and Growth Prospects 2034
Introduction
Buerger's Disease, also known as Thromboangiitis Obliterans, is a rare, chronic inflammatory disorder of small and medium-sized blood vessels, primarily in the limbs. Strongly associated with tobacco use, it leads to restricted blood flow, pain, ulcers, and in severe cases, gangrene that requires amputation. With no definitive cure available, management focuses on smoking cessation, vascular therapy, pain control, and in advanced cases, surgical interventions.
The global Buerger's Disease Market is steadily…
Batten Disease Market Detailed Industry Report Analysis 2025-2034
Introduction
Batten disease, or Neuronal Ceroid Lipofuscinosis (NCL), is a rare and fatal inherited disorder of the nervous system that primarily affects children. Characterized by progressive neurological impairment, seizures, vision loss, and cognitive decline, Batten disease poses a severe healthcare challenge with limited treatment options. Historically, management has focused on supportive care, but with advances in gene therapy, enzyme replacement therapies, and rare disease funding, the landscape is beginning to change.
In…
Acquired Hemophilia A Market Outlook 2024-2034
Introduction
Acquired Hemophilia A (AHA) is a rare but life-threatening autoimmune bleeding disorder caused by the development of autoantibodies against factor VIII. Unlike congenital hemophilia, AHA usually presents in older adults with no previous bleeding history, making it a highly challenging condition to diagnose and manage. Because of its unpredictable onset and severity, timely intervention and effective treatment remain critical.
In recent years, the market has seen significant progress due to the…
Human Papillomavirus (HPV)-Associated Diseases Market Outlook 2025-2034
Introduction
Human Papillomavirus (HPV) is one of the most common viral infections worldwide and is linked to a wide range of associated diseases, including cervical cancer, oropharyngeal cancer, anal cancer, and genital warts. While most HPV infections are self-limiting, persistent high-risk strains can cause life-threatening malignancies, making HPV a significant global public health challenge.
Over the past decade, increasing vaccination coverage, improved screening programs, and advances in targeted therapies have transformed the…
More Releases for Amyloidosis
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684
This latest report researches the industry structure,…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
Amyloidosis Treatment Market Size - Forecasts to 2026
As per the research conducted by GME, the Amyloidosis Treatment Market will grow with a CAGR value of 6.8 percent. The global amyloidosis treatment market is foreseen to rise rapidly throughout the forecast period because of the increasing likelihood of amyloidosis targeted therapies releases, a growing core patient demographic since they are biologically prone to amyloidosis, surging healthcare understanding amongst individuals, and increasing disposable incomes of consumers.
Browse 151 Market Data…
